NYT picks apart ADHD

Share this article:

The New York Times gives a clinical and marketing look at the uptick in the $9-billion dollar attention deficit disorder market. Among the topics covered are the nomenclature for one of the condition's hallmark drugs—Adderall, which was a combination of A.D.D. and All—and the professional and consumer marketing strategies that have helped cultivate a prescriptive landscape that psychiatrist Keith Conners tells the Gray Lady “make it look like an epidemic. Well, it's not. It's preposterous.”

The piece also touches on the prickly topic of pharmaceutical-sponsored speaking engagements (one industry-compensated orator says company money has not influenced his research) and patient-facing materials about ADHD surfacing in at least one school system as well as the relatively recent wave of adult ADHD awareness messaging, among other topics.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.